- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05571189
Rééducation à domicile après une embolie pulmonaire aiguë
The purpose of this study is to evaluate whether a home rehabilitation program after hospitalization for acute pulmonary embolism (PE) improves clinical outcomes at 3 months compared to usual care. Daily physical activity tasks that incorporate heart rate monitoring will be sent through email or text. This information could help improve the management of acute PE.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
New York
-
Rochester, New York, États-Unis, 14642
- University of Rochester Medical Center
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- English speaking (>18 years old). Daily messages will be sent in English.
- Acute PE with right ventricular enlargement or dysfunction defined by echocardiogram report, CT Angiogram report, or elevated cardiac biomarker (NT-pro BNP or troponin).
- Baseline testing started within 7 days of hospital discharge.
Exclusion Criteria:
- Pregnancy.
- Cardiac Effort >2.5 beats/m during 6MWT. This is for safety.
- Cardiac Effort <1.2 beats/m during 6MWT. They are unlikely to benefit.
- Resting tachycardia >120 beats/m during screening or at hospital discharge.
- Suspicion for Chronic Thromboembolic Pulmonary Hypertension.
- Systolic blood pressure >180 mmHg during screening or at hospital discharge.
- Inability to walk.
- Estimated prognosis <12 months at the time of discharge due to underlying co-morbidities.
- Advanced neurologic disease.
- Lack of access to email or text messaging.
- Inability to follow daily instructions.
- Participation in a structured exercise routine at least three days per week in the prior four weeks.
- Principal Investigator discretion
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Soins de soutien
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Participants who receive daily activity message
The intervention group will receive instructions for a daily activity sent through SMS text message or email. |
Participants will receive a text each day with instructions about the daily activity they should complete for that day. |
|
Comparateur placebo: Participants who receive control message
The control group will receive daily messages to help with blinding sent through text message or email. The messages will not include activity tasks and will include phrases such as "I hope you have a good day". |
Participants will receive a text each day with no instructions about daily activity. It will have messages like "have a nice day." |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
mean change in vector magnitude count as measured by actigraphy
Délai: 10 weeks
|
The Actigraph triaxial accelerometer will be used to monitor continuous activity at home on the non-dominant wrist. The accelerometer data will be downloaded and will include the vector magnitude count. |
10 weeks
|
|
mean change in mean amplitude deviation as measured by actigraphy
Délai: 10 weeks
|
The Actigraph triaxial accelerometer will be used to monitor continuous activity at home on the non-dominant wrist. The accelerometer data will be downloaded and will include the mean amplitude deviation. |
10 weeks
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
changement moyen en 6 minutes de marche
Délai: 12 semaines
|
12 semaines
|
|
|
variation moyenne de la fréquence cardiaque pendant une marche de 6 minutes
Délai: 12 semaines
|
12 semaines
|
|
|
proportion de sujets qui développent une hypertension pulmonaire thromboembolique chronique
Délai: 12 semaines
|
12 semaines
|
|
|
proportion of participants with post-PE syndrome
Délai: 12 weeks
|
Participants will be evaluated by a physician to determine if they have post PE-syndrome |
12 weeks
|
|
mean change in steps as measured by Actigraph
Délai: 12 weeks
|
The Actigraph triaxial accelerometer will be used to monitor the number of steps taken at home on the non-dominant wrist. The accelerometer data will be downloaded and will include the step count. |
12 weeks
|
|
mean change in activity as measured by Actigraph
Délai: 12 weeks
|
The Actigraph triaxial accelerometer will be used to monitor the amount of activity taken at home on the non-dominant wrist. The accelerometer data will be downloaded and will include the amount of activity. |
12 weeks
|
|
mean change in quality of life as measured by PROMIS
Délai: 12 weeks
|
The PROMIS questionnaire ranges from 0-99 with higher scores indicating worse outcome. |
12 weeks
|
|
mean change in quality of life as measured by Emphasis 10
Délai: 12 weeks
|
The Emphasis 10 questionnaire ranges from 0-50 with higher scores indicating worse quality of life. |
12 weeks
|
|
mean change in quality of life as measured by Pulmonary Embolism quality of life questionnaire
Délai: 12 weeks
|
The pulmonary embolism quality of life questionnaire ranges from 1 to 27 with higher scores indicating worse outcomes. |
12 weeks
|
|
mean change in oxygen use during a 6 minute walk
Délai: 12 weeks
|
Oxygen use will be measured by a measured by portable K5 metabolic analyzer. |
12 weeks
|
|
mean change in carbon dioxide production during a 6 minute walk
Délai: 12 weeks
|
Carbon Dioxide use will be measured by a measured by portable K5 metabolic analyzer. |
12 weeks
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Daniel Lachant, DO, University of Rochester
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- STUDY00007680
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .